Volume 14, Issue 3, Pages (March 2013)

Slides:

Advertisements

Similar presentations

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Advertisements

Volume 376, Issue 9753, Pages (November 2010)

Fever of unknown origin and cancer: a population-based study

Volume 17, Issue 12, Pages (December 2016)

Volume 367, Issue 9517, Pages (April 2006)

Volume 359, Issue 9323, Pages (June 2002)

Volume 376, Issue 9747, Pages (October 2010)

Volume 15, Issue 1, Pages (January 2014)

Volume 16, Issue 9, Pages (September 2015)

Clinically useful prognostic factors in acute myeloid leukemia

Long-term effects of hormone replacement therapy

Building better therapy for children with acute lymphoblastic leukemia

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 377, Issue 9783, Pages (June 2011)

Volume 13, Issue 12, Pages (December 2012)

Volume 373, Issue 9666, Pages (March 2009)

Volume 16, Issue 13, Pages (October 2015)

Volume 9, Issue 5, Pages (May 2008)

Volume 13, Issue 3, Pages (March 2012)

Volume 15, Issue 8, Pages (July 2014)

Long-term effects of hormone replacement therapy

Volume 366, Issue 9486, Pages (August 2005)

Volume 15, Issue 4, Pages (April 2014)

Volume 376, Issue 9757, Pages (December 2010)

Aspirin in the prevention of cancer – Author's reply

Volume 14, Issue 10, Pages (September 2013)

Volume 9, Issue 9, Pages (September 2008)

Volume 15, Issue 4, Pages (April 2014)

Volume 15, Issue 1, Pages (January 2014)

Gene therapy in haematology and oncology

Volume 9, Issue 10, Pages (October 2008)

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim.

Volume 18, Issue 3, Pages (March 2017)

Volume 379, Issue 9812, Pages (January 2012)

Volume 15, Issue 1, Pages (January 2014)

Volume 13, Issue 12, Pages (December 2012)

Volume 387, Issue 10023, Pages (March 2016)

Volume 6, Issue 6, Pages (June 2005)

Volume 11, Issue 4, Pages (April 2010)

Volume 9, Issue 9, Pages (September 2008)

Volume 14, Issue 11, Pages (October 2013)

Volume 373, Issue 9666, Pages (March 2009)

Volume 10, Issue 9, Pages (September 2009)

Volume 19, Issue 4, Pages (April 2018)

Volume 376, Issue 9753, Pages (November 2010)

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 378, Issue 9786, Pages (July 2011)

Volume 376, Issue 9757, Pages (December 2010)

Volume 9, Issue 4, Pages (April 2008)

Volume 15, Issue 6, Pages (May 2014)

Volume 381, Issue 9880, Pages (May 2013)

Volume 13, Issue 9, Pages (September 2012)

Volume 14, Issue 6, Pages (May 2013)

Volume 13, Issue 11, Pages (November 2012)

Volume 5, Issue 4, Pages (April 2018)

Volume 19, Issue 10, Pages (October 2018)

Volume 375, Issue 9714, Pages (February 2010)

Volume 11, Issue 3, Pages (March 2010)

Volume 11, Issue 1, Pages (January 2010)

Volume 376, Issue 9757, Pages (December 2010)

Volume 371, Issue 9618, Pages (March 2008)

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

Volume 375, Issue 9715, Pages (February 2010)

Volume 376, Issue 9747, Pages (October 2010)

Volume 372, Issue 9632, Pages (July 2008)

Volume 5, Issue 1, Pages (January 2018)

Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Clinic attendance and disengagement of young adults with type 1 diabetes after transition of care from paediatric to adult services (TrACeD): a randomised,

A Review of First-Line Treatment for Small-cell Lung Cancer

Presentation transcript:

Volume 14, Issue 3, Pages 199-209 (March 2013) Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial Prof Ajay Vora, FRCPath, Nick Goulden, PhD, Rachel Wade, MSc, Chris Mitchell, FRCPCH, Jeremy Hancock, PhD, Rachael Hough, MD, Clare Rowntree, PhD, Sue Richards, DPhil The Lancet Oncology Volume 14, Issue 3, Pages 199-209 (March 2013) DOI: 10.1016/S1470-2045(12)70600-9 Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 1 Outline of treatment regimens for clinical risk groups defined by National Cancer Institute criteria, cytogenetics, and early response IM=interim maintenance. DI=delayed intensification. BFM=Berlin–Frankfurt–Munster. MRD=minimal residual disease. MRD low-risk patients assigned to one delayed intensification receive DI1 and then receive continuing therapy. MRD high-risk patients assigned to the intensive schedule transferred to clinical high-risk regimen after induction. The Lancet Oncology 2013 14, 199-209DOI: (10.1016/S1470-2045(12)70600-9) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 2 Trial profile MRD=minimal residual disease. *One patient had Burkitt's lymphoma, one T-cell lymphoma, one T non-Hodgkin lymphoma, one mature B-cell acute lymphoblastic leukaemia, two acute myeloid leukaemia, five mixed-phenotype acute leukaemia, and one precursor B non-Hodgkin lymphoma. †Results not reported here; longer follow-up necessary. ‡No patients lost to follow-up before 1 year or excluded from analysis. The Lancet Oncology 2013 14, 199-209DOI: (10.1016/S1470-2045(12)70600-9) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 3 Event-free survival, relapse, and overall survival in the trial overall The Lancet Oncology 2013 14, 199-209DOI: (10.1016/S1470-2045(12)70600-9) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 4 Event-free survival and relapse in MRD low-risk patients MRD=minimal residual disease. The Lancet Oncology 2013 14, 199-209DOI: (10.1016/S1470-2045(12)70600-9) Copyright © 2013 Elsevier Ltd Terms and Conditions